Form 4: BioCryst Pharmaceuticals Director Steve Aselage Acquires Shares and Options

Director Steve Aselage received stock options and restricted stock units from BioCryst Pharmaceuticals on June 12, 2024.

Summary

• On June 12, 2024, Steve Aselage, a director at BioCryst Pharmaceuticals, acquired 6,820 shares of common stock at $0.
• These shares were received as an automatic non-employee director grant of Restricted Stock Units.
• These Restricted Stock Units will vest on the first anniversary of the grant date.
• Aselage also received an automatic non-employee director grant of stock options for 49,933 shares with an exercise price of $6.30.
• These options vest on June 12, 2025, and expire on June 12, 2034.
• Following these transactions, Aselage directly owns 49,933 shares and indirectly owns 2,500 shares through a trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects standard compensation practices. The director's acquisition of shares and options could be seen as a positive sign, but it's a routine event.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can influence investor sentiment.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder confidence due to the director's increased stake in the company.

Key Dates